メニュー
Search and analyze patents including FTO (Freedom to Operate) analysis, patent landscape mapping, and competitive IP intelligence. Keywords: patent, FTO, freedom to operate, IP, intellectual property
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
SOC 職業分類に基づく
Global drug development pipeline tracking by disease, target, mechanism, or company. Use for competitive intelligence, opportunity identification, and trend analysis. Keywords: pipeline, drug development, clinical trials, R&D tracking, competitive landscape
Structure-based similarity search and scaffold analysis for drug discovery. Use for lead hopping, scaffold morphing, and chemical space exploration. Keywords: similarity search, scaffold hopping, chemical space, fingerprint, Tanimoto
Analyze target competitive landscape including existing drugs, pipeline companies, differentiation opportunities, and market maturity assessment. Keywords: target competition, landscape, differentiation, pipeline analysis, market share
Target safety assessment including known toxicities, essentiality, and off-target concerns. Use for early safety risk evaluation and target selection. Keywords: target safety, toxicity, essential gene, knockout, safety risks
Comprehensive target validation assessing druggability, disease association strength, tractability, and competitive landscape. Use for go/no-go decisions on target selection. Keywords: target validation, druggability, tractability, disease association, genetic validation
ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction for drug candidates. Use for assessing drug-likeness, PK properties, and safety risks early in drug discovery. Keywords: ADMET, PK, toxicity, drug-likeness, DILI, hERG, bioavailability
| name | patent-search |
| description | Search and analyze patents including FTO (Freedom to Operate) analysis, patent landscape mapping, and competitive IP intelligence. Keywords: patent, FTO, freedom to operate, IP, intellectual property |
| category | Patent Analysis |
| tags | ["patent","fto","ip","landscape","claims"] |
| version | 1.0.0 |
| author | Drug Discovery Team |
| dependencies | ["uspto-database","epo-database","wipo-database"] |
Comprehensive patent analysis for drug discovery and IP intelligence.
/patent EGFR inhibitor
/fto "quinazoline EGFR kinase"
/patent-map KRAS G12C
Analyze patent landscape for osimertinib
| Section | Description | Data Source |
|---|---|---|
| Patent Search | Find relevant patents | USPTO, EPO, WIPO |
| Patent Details | Claims, assignees, priority | Patent databases |
| FTO Analysis | Freedom to operate assessment | Claims analysis |
| Landscape Map | Patent clustering and gaps | Aggregated |
| Expiration | Patent expiry dates | Patent databases |
| Family Analysis | Patent family members | Global Dossier |
# Patent Analysis: EGFR Inhibitors
## Executive Summary
**Total Patents**: 3,247 EGFR inhibitor patents found
**Key Patent Families**: 89 unique families
**FTO Risk**: High - crowded landscape with broad claims
## Patent Landscape
| Time Period | Patents | Growth |
|-------------|---------|--------|
| 1990-1999 | 234 | Baseline |
| 2000-2009 | 892 | +281% |
| 2010-2019 | 1,456 | +63% |
| 2020-2024 | 665 | Declining |
## Key Patent Families
### US5747498 (Erlotinib)
| Field | Value |
|-------|-------|
| Assignee | OSI Pharmaceuticals |
| Priority Date | 1994-04-15 |
| Grant Date | 1998-05-05 |
| Expiry | 2018 (expired) |
| Claims | 47 claims |
| Scope | Quinazoline EGFR inhibitors |
### US8017621 (Gefitinib)
| Field | Value |
|-------|-------|
| Assignee | AstraZeneca |
| Priority Date | 1992-03-06 |
| Expiry | 2014 (expired) |
| Scope | Broad EGFR TKI claims |
## FTO Analysis
### High-Risk Patents
| Patent | Risk | Reason |
|--------|------|--------|
| US8772358 | ⚠️ High | 3rd-gen TKI, C797S active |
| US10363010 | ⚠️ High | Broad mutant-selective claims |
| US10588034 | ⚠️ High | Combination therapy claims |
### White Space
| Area | Opportunity | Rationale |
|------|-------------|----------|
| 4th-gen TKI | Low IP pressure | C797S+S1278 niche |
| Allosteric sites | Emerging | Fewer existing claims |
| Bispecific formats | Moderate | Combination IP possible |
## Patent Family Analysis
**Example: Osimertinib (AZD9291)**
| Jurisdiction | Patent | Status | Expiry |
|-------------|--------|--------|--------|
| US | US8772358 | Expired | 2033 |
| EP | EP2378967 | Granted | 2033 |
| JP | JP5958971 | Granted | 2033 |
| CN | CN102822420 | Granted | 2033 |
## Claim Analysis
**US8772358 Claim 1 (Representative):**
A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disease mediated by EGFR having the T790M mutation...
**Breadth:** Broad - covers mutant-selective EGFR inhibitors
**Enforceability:** High - well-defined structure
**Workaround:** Difficult - covers core scaffold
## Competitive IP Map
| Company | Patent Families | Core Focus |
|----------|-----------------|-------------|
| AstraZeneca | 12 | 3rd-gen TKI, combinations |
| Johnson & Johnson | 8 | Bispecific antibodies |
| Daiichi Sankyo | 6 | ADC conjugates |
| Blueprint Medicines | 4 | 4th-gen TKI |
| Yuhan/Roche | 3 | Lazertinib combinations |
/patent EGFR quinazoline
/patent-search "KRAS G12C inhibitor"
Find all patents for sotorasib
/fto "EGFR TKI scaffold"
/fto-analysis compound.smi
Can I make this compound without infringement?
/patent-map KRAS inhibitors
Map patent landscape for 4th-gen EGFR
Analyze IP gaps in PROTAC EGFR degraders
/patent US8772358 --family
/patent WO2010130291 --global
Show all related patents for osimertinib
# Search patents by keyword
python scripts/patent_search.py "EGFR inhibitor" --output patents.json
# FTO analysis
python scripts/patent_search.py --fto "quinazoline scaffold" --claims
# Patent family lookup
python scripts/patent_search.py --family US8772358
# Landscape mapping
python scripts/patent_search.py --landscape "KRAS G12C" --cluster
# Expiration analysis
python scripts/patent_search.py --expiry "EGFR TKI" --sort-by-date
pip install requests pandas lxml
| Pitfall | Solution |
|---|---|
| Narrow search | Use multiple terms/synonyms |
| Ignoring families | Check global coverage |
| Misreading claims | Claims define scope, not title |
| Overlooked continuations | Check continuation-in-part (CIP) |
| Publication vs. grant | Check granted patent status |